3,327 reports of this reaction
5.6% of all BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE reports
#2 most reported adverse reaction
DRUG WITHDRAWAL SYNDROME is the #2 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, manufactured by INDIVIOR INC.. There are 3,327 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE to DRUG WITHDRAWAL SYNDROME. This represents approximately 5.6% of all 59,605 adverse event reports for this drug.
Patients taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE who experience drug withdrawal syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG WITHDRAWAL SYNDROME is moderately reported among BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to drug withdrawal syndrome, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:
The following drugs have also been linked to drug withdrawal syndrome in FDA adverse event reports:
DRUG WITHDRAWAL SYNDROME has been reported as an adverse event in 3,327 FDA reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG WITHDRAWAL SYNDROME accounts for approximately 5.6% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience drug withdrawal syndrome while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.